Company Overview

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that address unmet medical needs, particularly in rare diseases and underserved therapeutic areas. The company operates primarily within the biotechnology and pharmaceutical industries, using a decentralized operating model built around independent subsidiaries known as “Vants.” Its business model emphasizes late-stage and mid-stage drug development, often acquiring or in-licensing assets that have been deprioritized by larger pharmaceutical companies and advancing them through regulatory approval and commercialization.

Founded in 2014, Roivant was established to address inefficiencies in traditional pharmaceutical R&D by combining centralized expertise with lean, asset-focused subsidiaries. Over time, the company evolved from a diversified portfolio of early-stage Vants into a more focused organization, increasingly prioritizing immunology, dermatology, and rare diseases, while also building a technology platform to support drug development and patient engagement.

Business Operations

Roivant generates value primarily through the development and commercialization of therapeutics via its subsidiaries, including Dermavant Sciences, Immunovant, Priovant Therapeutics, and Arcutis Biotherapeutics (historically a majority-owned subsidiary prior to its public listing). Revenue has been driven by product sales, milestone payments, royalties, and strategic transactions, with commercial products including VTAMA® (tapinarof) cream for dermatologic conditions. The company also generates cash flow through equity stakes in publicly traded Vants.

Operations are supported by Roivant Discovery, a centralized platform that provides shared services such as clinical development, regulatory strategy, data science, and manufacturing oversight. Roivant maintains strategic partnerships and licensing agreements with global pharmaceutical companies and academic institutions, while retaining operational control at the subsidiary level to accelerate decision-making and execution.

Strategic Position & Investments

Roivant’s strategy centers on capital-efficient drug development, portfolio optimization, and selective monetization of assets to fund new growth opportunities. The company has pursued this through acquisitions of clinical-stage compounds, the formation and spin-out of Vants, and equity investments in subsidiaries that later access public markets. Notable strategic actions include the formation of Priovant Therapeutics in collaboration with Pfizer and the continued investment in Immunovant to advance autoimmune disease therapies.

In parallel, Roivant has invested in technology-enabled platforms such as Datavant, a health data technology company focused on secure data sharing and interoperability. This investment reflects Roivant’s broader interest in leveraging data, analytics, and digital infrastructure to improve clinical development efficiency and healthcare outcomes.

Geographic Footprint

Roivant is headquartered in Bermuda, with principal operational offices in the United States, particularly in New York and Boston, which serve as hubs for corporate management, research, and clinical development. The company’s subsidiaries conduct clinical trials and commercialization activities across North America, Europe, and parts of Asia, depending on therapeutic focus and regulatory pathways.

Internationally, Roivant maintains a presence through clinical trial sites, regulatory engagements, and commercial partnerships, giving it exposure to major pharmaceutical markets while limiting fixed infrastructure outside its core regions. This global but asset-light footprint supports flexibility and scalability across multiple therapeutic areas.

Leadership & Governance

Roivant was founded by Vivek Ramaswamy, who shaped the company’s decentralized operating philosophy and focus on capital efficiency. The current leadership emphasizes disciplined portfolio management, scientific rigor, and long-term value creation through both drug commercialization and strategic investments. Governance is supported by an experienced board with backgrounds in pharmaceuticals, finance, and technology.

Key executives include:

• Matthew Gline – Chief Executive Officer
• Lokesh Jain – Chief Financial Officer
• Ramakrishna Venugopalan – President and Chief Investment Officer
• J. Michael Robertson – Chief Operating Officer
• Alison McFarlane – Chief Legal Officer and Corporate Secretary

The leadership team’s strategic vision centers on advancing differentiated medicines while maintaining financial discipline and leveraging Roivant’s platform model to repeatedly build and scale successful biopharmaceutical businesses.